- A new clinical trial in Italy investigates the efficacy of oral semaglutide.
- Semaglutide and other GLP-1 agonist drugs to treat diabetes, cardiovascular health, and weight loss, are most widely available as injectable medications.
- The study finds that oral versions of the drug perform best in patients in the early stages of diabetes, and not as well as injectables for other people.
- Even though doses of oral semaglutide are significantly larger than injectable medications, far less of it gets into the blood stream, potentially reducing its effectiveness.
Semaglutide, the active ingredient in diabetes drugs that have also become popular as a weight-loss aid, is primarily available in injectable form.
This includes the two most widely used drugs, Wegovy and Ozempic. Rybelsus is currently the only oral semaglutide drug on the market.
In a new Italian study conducted in a clinical setting, oral semaglutide was found to be most effective in people with a recent diagnosis of diabetes, with “suboptimal” benefits for other diabetes patients.
The study’s results suggest that oral semaglutide may be of most use in the early stages of diabetes.
People whose diabetes was recently diagnosed showed significant improvements in levels of HbA1c — a measurement of blood sugar — and their body weight.
The study results appear in the Journal of Clinical Medicine.
Wonderful beat I wish to apprentice while you amend your web site how could i subscribe for a blog web site The account aided me a acceptable deal I had been a little bit acquainted of this your broadcast provided bright clear idea
Usually I do not read article on blogs however I would like to say that this writeup very compelled me to take a look at and do so Your writing taste has been amazed me Thanks quite nice post